A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Launched by ASTRAZENECA · Aug 2, 2023
Trial Information
Current as of October 02, 2025
Recruiting
Keywords
ClinConnect Summary
The eVOLVE-Lung02 clinical trial is studying a new treatment for patients with metastatic non-small cell lung cancer (NSCLC), which is a type of lung cancer that has spread to other parts of the body. This trial is comparing two treatment options: one that includes a drug called volrustomig combined with chemotherapy, and another that combines a drug called pembrolizumab with chemotherapy. The goal is to see which combination works better and is safer for patients with a specific type of NSCLC who have a certain level of a protein called PD-L1.
To participate in this trial, patients should be between the ages of 65 and 74 and have a confirmed diagnosis of stage IV non-small cell lung cancer that cannot be treated with surgery or radiation. Participants should not have specific genetic changes in their tumors that would make them eligible for other targeted treatments. Throughout the trial, participants will receive treatment and have regular check-ups to monitor their health and how well the treatments are working. If you or a loved one are considering joining this study, it's important to discuss it with your healthcare team to see if it’s a good fit.
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Histologically or cytologically documented squamous or non-squamous NSCLC.
- • Stage IV NSCLC (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology 2016), not amenable to curative surgery or radiation.
- • Absence of sensitizing EGFR mutations and ALK and ROS1 rearrangements.
- • Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted first-line therapies.
- Key Exclusion Criteria:
- • Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant. Rare subtypes are excluded.
- • Spinal cord compression.
- • Symptomatic brain metastases. Brain metastases may be treated or untreated, but participants must be asymptomatic and off steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and study enrollment.
- * History of another primary malignancy except for:
- • 1. Malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence.
- • 2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
- • 3. Adequately treated carcinoma in situ without evidence of disease.
- • As judged by the investigator, any condition that would interfere with evaluation of the study intervention or interpretation of participant safety or study results.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Fairfax, Virginia, United States
Nashville, Tennessee, United States
Indianapolis, Indiana, United States
Towson, Maryland, United States
Detroit, Michigan, United States
Gent, Belgium
Barretos, Brazil
Praha 2, Czechia
Székesfehérvár, Hungary
Trnava, Slovakia
Madrid, Spain
Long Beach, California, United States
Tacoma, Washington, United States
Dresden, Germany
Columbus, Ohio, United States
Tuebingen, Germany
Gainesville, Florida, United States
Portland, Oregon, United States
Albany, New York, United States
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Winnipeg, Manitoba, Canada
Toronto, Ontario, Canada
Caen, France
Padova, Italy
Antwerpen, Belgium
Budapest, Hungary
Milano, Italy
Barcelona, Spain
Linz, Austria
Wels, Austria
Heidelberg, Australia
Bordeaux, France
Lille, France
Bari, Italy
Nieuwegein, Netherlands
Lublin, Poland
Des Moines, Iowa, United States
Baltimore, Maryland, United States
Pittsburgh, Pennsylvania, United States
Oshawa, Ontario, Canada
Debrecen, Hungary
Levis, Quebec, Canada
Denver, Colorado, United States
Saint Petersburg, Florida, United States
Marrero, Louisiana, United States
Annapolis, Maryland, United States
Grand Island, Nebraska, United States
Lincoln, Nebraska, United States
Memphis, Tennessee, United States
Aalst, Belgium
Pavia, Italy
Omaha, Nebraska, United States
Tallahassee, Florida, United States
Newark, Delaware, United States
Lexington, Kentucky, United States
Quimper Cedex, France
Freiburg, Germany
Halle, Germany
Nürnberg, Germany
Paris Cedex 5, France
Houston, Texas, United States
Columbus, Ohio, United States
Halifax, Nova Scotia, Canada
La Plata, Argentina
Sao Paulo, Brazil
Deszk, Hungary
Johannesburg, South Africa
Taipei, Taiwan
Heidelberg, Germany
Kecskemét, Hungary
Törökbálint, Hungary
Málaga, Spain
West Palm Beach, Florida, United States
South Brisbane, Australia
Amsterdam, Netherlands
Fitzroy, Australia
Bratislava, Slovakia
Fort Myers, Florida, United States
Hattiesburg, Mississippi, United States
Dayton, Ohio, United States
Irving, Texas, United States
Beijing, China
Beijing, China
Chongqing, China
Ravenna, Italy
Olsztyn, Poland
Bloemfontein, South Africa
Tainan, Taiwan
Roma, Italy
Kosice, Slovakia
Birmingham, United Kingdom
Prescott, Arizona, United States
Fort Wayne, Indiana, United States
Tianjin, China
Taoyuan, Taiwan
Des Moines, Iowa, United States
Baton Rouge, Louisiana, United States
East Syracuse, New York, United States
New Delhi, India
Nagoya Shi, Japan
Suwon Si, Korea, Republic Of
Barrie, Ontario, Canada
Koblenz, Germany
Pretoria, South Africa
Truro, United Kingdom
Matsuyama Shi, Japan
Clayton, Australia
Curitiba, Brazil
Guangzhou, China
Nanning, China
Pécs, Hungary
Szekszárd, Hungary
Lublin, Poland
Parktown, South Africa
Soweto, South Africa
Kaohsiung, Taiwan
Bayonne, France
Kashiwa, Japan
Koto Ku, Japan
Essen, Germany
George, South Africa
Bonn, Germany
Reims, France
Montpellier, France
Marseille, France
Ludwigsburg, Germany
Palo Alto, California, United States
Changchun, China
Shanghai, China
Taiyuan, China
Wuhan, China
Parma, Italy
Monterrey, Mexico
Seoul, Korea, Republic Of
Gauting, Germany
London, United Kingdom
Lone Tree, Colorado, United States
Blackpool, United Kingdom
Toruń, Poland
Nanchang, China
Gyöngyös, Hungary
Cheongju Si, Korea, Republic Of
Groningen, Netherlands
Belleville, New Jersey, United States
Rosario, Argentina
Chicoutimi, Canada
Changsha, China
Limoges, France
Alicante, Spain
Porto Alegre, Brazil
Colchester, United Kingdom
Okayama Shi, Japan
Strasbourg Cedex, France
Gyöngyös Mátraháza, Hungary
Bergamo, Italy
Nanjing, China
Bengbu, China
Hangzhou, China
Yangzhou, China
Zhengzhou, China
Kawasaki Shi, Japan
Yokohama Shi, Japan
Győr, Hungary
Osaka Shi, Japan
Daegu, Korea, Republic Of
Hsinchu, Taiwan
Antalya, Turkey
Incheon, Korea, Republic Of
Bonn, Germany
Tainan City, Taiwan
Catanzaro, Italy
Banska Bystrica, Slovakia
Sendai Shi, Japan
Ube Shi, Japan
Muang, Thailand
Olomouc, Czechia
Praha, Czechia
Tilburg, Netherlands
Springdale, Arkansas, United States
Sagamihara Shi, Japan
Suwon, Korea, Republic Of
Taipei City, Taiwan
Rzeszów, Poland
Amanzimtoti, South Africa
Poznań, Poland
Rosario, Argentina
Warszawa, Poland
New Taipei, Taiwan
Velbert, Germany
Rondebosch, South Africa
Bilbao (Vizcaya), Spain
Toulon Naval, France
Fukuoka Shi, Japan
Osakasayama Shi, Japan
Ankara, Turkey
Praha, Czechia
Orlando, Florida, United States
Immenhausen, Germany
Lanzhou, China
Linhai, China
Florianópolis, Brazil
Istanbul, Turkey
Fresh Meadows, New York, United States
Córdoba, Argentina
Fortaleza, Brazil
Louisville, Kentucky, United States
Sydney, Australia
Pamukkale, Turkey
Ostrava Vitkovice, Czechia
Hangzhou, China
Xi'an, China
Tomaszów Mazowiecki, Poland
Songkhla, Thailand
Chengdu, China
Lampang, Thailand
Diyarbakir, Turkey
Suresnes, France
Hefei, China
Yunlin, Taiwan
Hyderabad, India
Mysuru, India
Radom, Poland
Fuzhou, China
Gütersloh, Germany
Georgsmarienhuette, Germany
Natal, Brazil
Bunkyo Ku, Japan
Nagpur, India
Johannesburg, South Africa
Mexico City, Mexico
Culiacan, Mexico
Caba, Argentina
Westbury, New York, United States
Lévis, Quebec, Canada
Palma, Spain
Shenzhen, China
Lancaster, Texas, United States
Hot Springs National Park, Arkansas, United States
Rio De Janeiro, Brazil
Silver Spring, Maryland, United States
Nashik, India
Jinju Si, Korea, Republic Of
Berlin Zehlendorf, Germany
Przemysl, Poland
çankaya, Turkey
Ciudad De México, Mexico
Delhi, India
Angers, France
Buenos Aires, Argentina
Henrico, Virginia, United States
Varanasi, India
Braunschweig, Germany
Chengdu, China
Szklarska Poręba, Poland
łódź, Poland
Bury St Edmunds, United Kingdom
Guadalajara, Mexico
Fatih Istanbul, Turkey
Ciudad Autónoma De Buenos Aire, Argentina
Ciudad De Córdoba, Argentina
Avignon, France
Saint Malo, France
Pietermaritzburg, South Africa
İzmir, Turkey
Bengaluru, India
Kolkata, India
Santa Cruz Do Sul, Brazil
Trois Rivières, Quebec, Canada
Hamburg, Germany
Naucalpan, Mexico
Horsham, Pennsylvania, United States
Denver, Colorado, United States
Sapporo Shi, Japan
Quimper, France
Calgary, Alberta, Canada
Linyi, China
Bengbu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported